

| H1500.H15T L | .ot | No. | 512 |
|--------------|-----|-----|-----|
|--------------|-----|-----|-----|

Cryopreserved Human Hepatocytes

| | Donor Information | |
|------------------------|-------------------|--|
| Demographics | Serology | |
| Gender: Female | CMV: (-) | |
| Age: 62 Years | HIV: (-) | |
| Race: Caucasian | HBV: (-) | |
| Cause of Death: Anoxia | HCV: (-) | |

Assured Minimum Yield: 4.0 x 10⁶ per vial

Viability: 92.0%

(Yield and viability are based on experiments performed at XenoTech using XenoTech's thawing protocol and K2000 Hepatocyte Isolation Kit.)

| Transporter ¹ | Marker substrate uptake (pmol/million cells/min) ^{2§} | | |
|--------------------------|--|----------------------|--|
| OATP NTCP | Estrone-3-sulfate Taurocholic Acid | 47 ± 13 5.5 ± 1.4 | |
| OCT1 | 1-Methyl-4-phenylpyridinium lodine | 18 ± 6 | |
| Enzyme | Marker substrate reaction (pmol/million cells | /min) | |
| CYP2D6 | Dextromethorphan O-demethylation | 66.8 | |
| CYP2E1 | Chlorzoxazone 6-hydroxylation | 86.9 | |
| CYP3A4/5 | Testosterone 6β-hydroxylation | 43.7 | |
| UGT | Glucuronidation of 4-Methylumbelliferone | 366 | |

¹ OATP (Organic Anion Transporting Polypeptide), NTCP (Sodium Taurocholate Co-transporting Polypeptide), OCT1 (Organic Cation Transporter)

CAUTION: These hepatocyte samples are from donors who tested negative for HIV and hepatitis. However, we recommend that these samples be considered as potential biohazards and that universal precautions be used when working with human derived products.

Store vials in liquid nitrogen, vapor phase.



² Data reflect mean and standard deviation from three separate assays performed on three separate days.

[§] Characterization based on methods described in: Hallifax D and Houston JB (2006) Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metabolism and Diposition 34:1829-1836